Analyst Price Targets — SLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 28, 2024 8:03 am | Keay Nakae | Chardan Capital | $55.00 | $19.00 | TheFly | Silence Therapeutics price target raised to $55 from $42 at Chardan |
| June 28, 2024 7:44 am | Michael Ulz | Morgan Stanley | $49.00 | $19.00 | TheFly | Silence Therapeutics price target raised to $49 from $45 at Morgan Stanley |
| March 13, 2024 11:01 am | Kostas Biliouris | BMO Capital | $67.00 | $25.61 | StreetInsider | BMO Capital Reiterates Silence Therapeutics (SLN) as Top Pick, 'buy the dip' |
| December 9, 2022 7:26 am | — | Morgan Stanley | $18.00 | $15.23 | Benzinga | Morgan Stanley Initiates Coverage On Silence Therapeutics with Equal-Weight Rating, Announces Price Target of $18 |
| November 17, 2022 8:28 am | — | Chardan Capital | $29.00 | $13.21 | Benzinga | Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $29 |
Latest News for SLN
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ: SLN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Insider and Institutional Ownership 87.1% of Avalo
The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent business achievements. “The past year was focused on clinical execution, demonstrated by the expedited…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLN.
U.S. House Trading
No House trades found for SLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.